Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-HBV in healthy volunteers and chronic hepatitis B patients
NCT03365947Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Apr 2020
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 3
01
Overview
A Phase 2 trial of tomligisiran in hepatitis B (HBV), sponsored by Arrowhead Pharmaceuticals. Started Mar 2018; status: completed.
02
Drugs
tomligisiran
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03365947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03365947.